Literature DB >> 31977040

Dynamic borrowing in the presence of treatment effect heterogeneity.

Ales Kotalik1, David M Vock1, Eric C Donny2, Dorothy K Hatsukami3,4, Joseph S Koopmeiners1.   

Abstract

A number of statistical approaches have been proposed for incorporating supplemental information in randomized clinical trials. Existing methods often compare the marginal treatment effects to evaluate the degree of consistency between sources. Dissimilar marginal treatment effects would either lead to increased bias or down-weighting of the supplemental data. This represents a limitation in the presence of treatment effect heterogeneity, in which case the marginal treatment effect may differ between the sources solely due to differences between the study populations. We introduce the concept of covariate-adjusted exchangeability, in which differences in the marginal treatment effect can be explained by differences in the distributions of the effect modifiers. The potential outcomes framework is used to conceptualize covariate-adjusted and marginal exchangeability. We utilize a linear model and the existing multisource exchangeability models framework to facilitate borrowing when marginal treatment effects are dissimilar but covariate-adjusted exchangeability holds. We investigate the operating characteristics of our method using simulations. We also illustrate our method using data from two clinical trials of very low nicotine content cigarettes. Our method has the ability to incorporate supplemental information in a wider variety of situations than when only marginal exchangeability is considered.
© The Author 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Data aggregation; Exchangeability; Historical data; Marginal treatment effects; Supplemental data

Mesh:

Year:  2021        PMID: 31977040      PMCID: PMC8511947          DOI: 10.1093/biostatistics/kxz066

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  11 in total

1.  Summarizing historical information on controls in clinical trials.

Authors:  Beat Neuenschwander; Gorana Capkun-Niggli; Michael Branson; David J Spiegelhalter
Journal:  Clin Trials       Date:  2010-02       Impact factor: 2.486

2.  Covariate-adjusted borrowing of historical control data in randomized clinical trials.

Authors:  Baoguang Han; Jia Zhan; Z John Zhong; Dawei Liu; Stacy Lindborg
Journal:  Pharm Stat       Date:  2017-05-31       Impact factor: 1.894

3.  Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial.

Authors:  Dorothy K Hatsukami; Xianghua Luo; Joni A Jensen; Mustafa al'Absi; Sharon S Allen; Steven G Carmella; Menglan Chen; Paul M Cinciripini; Rachel Denlinger-Apte; David J Drobes; Joseph S Koopmeiners; Tonya Lane; Chap T Le; Scott Leischow; Kai Luo; F Joseph McClernon; Sharon E Murphy; Viviana Paiano; Jason D Robinson; Herbert Severson; Christopher Sipe; Andrew A Strasser; Lori G Strayer; Mei Kuen Tang; Ryan Vandrey; Stephen S Hecht; Neal L Benowitz; Eric C Donny
Journal:  JAMA       Date:  2018-09-04       Impact factor: 56.272

4.  Bayesian hierarchical modeling based on multisource exchangeability.

Authors:  Alexander M Kaizer; Joseph S Koopmeiners; Brian P Hobbs
Journal:  Biostatistics       Date:  2018-04-01       Impact factor: 5.899

5.  Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials.

Authors:  Brian P Hobbs; Bradley P Carlin; Sumithra J Mandrekar; Daniel J Sargent
Journal:  Biometrics       Date:  2011-03-01       Impact factor: 2.571

6.  Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models.

Authors:  Brian P Hobbs; Daniel J Sargent; Bradley P Carlin
Journal:  Bayesian Anal       Date:  2012-08-28       Impact factor: 3.728

7.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.

Authors:  T F Heatherton; L T Kozlowski; R C Frecker; K O Fagerström
Journal:  Br J Addict       Date:  1991-09

Review 8.  Bayesian clinical trials.

Authors:  Donald A Berry
Journal:  Nat Rev Drug Discov       Date:  2006-01       Impact factor: 84.694

Review 9.  Use of historical control data for assessing treatment effects in clinical trials.

Authors:  Kert Viele; Scott Berry; Beat Neuenschwander; Billy Amzal; Fang Chen; Nathan Enas; Brian Hobbs; Joseph G Ibrahim; Nelson Kinnersley; Stacy Lindborg; Sandrine Micallef; Satrajit Roychoudhury; Laura Thompson
Journal:  Pharm Stat       Date:  2013-08-05       Impact factor: 1.894

10.  Semiparametric Bayesian commensurate survival model for post-market medical device surveillance with non-exchangeable historical data.

Authors:  Thomas A Murray; Brian P Hobbs; Theodore C Lystig; Bradley P Carlin
Journal:  Biometrics       Date:  2013-12-05       Impact factor: 2.571

View more
  2 in total

1.  A group-sequential randomized trial design utilizing supplemental trial data.

Authors:  Ales Kotalik; David M Vock; Brian P Hobbs; Joseph S Koopmeiners
Journal:  Stat Med       Date:  2021-11-09       Impact factor: 2.373

Review 2.  Comparative Study of Bayesian Information Borrowing Methods in Oncology Clinical Trials.

Authors:  Liwen Su; Xin Chen; Jingyi Zhang; Fangrong Yan
Journal:  JCO Precis Oncol       Date:  2022-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.